Domestic Manufacturing Boom: 12 Best Pharma Stocks to Invest in Now

9. Novo Nordisk A/S (NYSE:NVO)

Number of Hedge Fund Holders: 64

Novo Nordisk A/S (NYSE:NVO) is a global healthcare company specializing in diabetes care. It develops, discovers, manufactures, and markets pharmaceutical products. Its operations are divided into two business segments: biopharmaceuticals and diabetes and obesity care. The latter segment covers GLP-1, insulin, and other protein-related products.

Novo Nordisk A/S (NYSE:NVO) is one of the two major pharmaceutical companies competing in the GLP-1 weight loss market, with the other being Eli Lilly. It ranks ninth on our list of the best pharma stocks to buy now amid the domestic manufacturing boom.

On May 7, Novo Nordisk A/S (NYSE:NVO) reported solid performance in its fiscal Q1 2025 results, with sales rising by 19% in Danish kroner and operating profit growing by 22%. The growth was attributed to a notable 67% growth in obesity care sales and the continuous expansion of GLP-1 diabetes treatments.

The company, however, adjusted its full-year outlook because of lower-than-anticipated penetration of branded GLP-1 treatments in the US. It is actively fighting unlawful compounding and expanding patient access to its treatments.

On May 8, UBS analyst Jo Walton maintained a Buy rating on Novo Nordisk A/S (NYSE:NVO) because of its solid performance, setting a price target of DKK700.00.